Therapeutic Areas Hepatology


Hepatology research includes a wide array of diseases affecting liver function that can stem from diverse etiologies including autoimmune conditions, malnutrition, cancer, and infectious disease complications. CTI’s therapeutic expertise specific to liver diseases is one of the driving forces behind our ability to successfully design and manage drug development programs in this area. We specialize in the unique challenges associated with hepatic populations, from mild to moderate liver disease to end stage acute and chronic liver disease. Our Medical Directors, including a former transplant surgeon, work closely with the rest of our organization so that project teams are familiar with hepatic diseases and associated complications. We attend industry meetings and are members of many hepatology related societies, including the American Association of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the International Liver Transplantation Society (ILTS), and Studies in Pediatric Liver Transplantation (SPLIT)

Miranda Sheeks, MS
Assistant Director, Clinical Project Management 
Miranda’s home-grown expertise has become invaluable asset to both our organization and to the sponsors we serve as she continues to make significant contributions to ongoing clinical trials inclusive of complex programs in hepatology. She has grown from an RA to a director level, where she now mentors our current RAs and project coordinators. Miranda was rconized as a finalist in the "Technology, Manufacturing, and Design" cateogry at the Northern Kentucky Young Professionals 10th Annual Next Generation Leadership Awards.

Miranda Sheeks

Some of our adult and pediatric experience includes:

  • Alcoholic cirrhosis
  • Autoimmune hepatitis
  • Chron's Disease
  • Delayed graft function (DGF)
  • Early allograft dysfunction
  • Fibrosis
  • Hepatic encephalopathy
  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Hepatitis D virus (HDV)
  • Hepatocellular carcinoma
  • Ischemia reperfusion injury (IRI)
  • Liver transplant
  • Metabolic liver disease
  • Nonalcoholic steatohepatitis (NASH)
  • Organ rejection (acute cellular rejection [ACR] and antibody mediated rejection [AMR])
  • Phenylketonuria
  • Primary biliary cirrhosis
  • Short bowl syndrome
  • Thrombo-cytopenia
  • Ulcerative Colitis
  • Urea cycle Disorder
  • Lysosomal Acid Lipase Deficiency (LALD)

We offer our sponsors:

Request Information

Icon Contact Small Retina

CTI is ready to help with your next drug development project

Contact Us